Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01011335
Recruitment Status : Completed
First Posted : November 11, 2009
Results First Posted : December 12, 2017
Last Update Posted : December 12, 2017
Nabi Biopharmaceuticals
Information provided by (Responsible Party):
David Tribble, Uniformed Services University of the Health Sciences

Brief Summary:
This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body. The purpose of this study is to find the right dose of a new vaccine that is safe and produces a good immune response (how well your body recognizes and defends itself against harmful foreign substances). There are two Staphylococcus aureus toxoids (components or antigens) under investigation in this study; one of them is a protein known as rAT and the other is a protein known as rLukS-PV. They are being developed to see if they are effective at preventing infections caused by the bacteria Staphylococcus aureus.

Condition or disease Intervention/treatment Phase
Staphylococcus Aureus Biological: Monovalent rAT Biological: Monovalent rLukS-PV Biological: Bivalent rLukS-PV / rAT Biological: Placebo with adjuvant Biological: Placebo Phase 1 Phase 2

Detailed Description:

Staphylococcus aureus is a leading cause of skin and soft tissue infections. Antibiotic resistance, such as seen with new community-acquired methicillin-resistant strains, presents a major challenge in treating and preventing these infections. Therefore, a preventative vaccine is considered a potentially better approach.

This study assesses the safety and immunogenicity of monovalent and bivalent S. aureus vaccine components. Healthy adult subjects will be randomized to receive 1 dose of monovalent or bivalent toxoid vaccine, or placebo in a dose escalation schedule.

Antigen-specific antibody will be measured by ELISA in sera collected for three months after injection. Safety data will be collected as 7 day reactogenicity diaries after each injection, adverse events and Staphylococcus aureus and skin and soft tissue infections will be collected through Day 84, and serious adverse events and chronic illnesses will be collected for the full 6 month study period.

To evaluate the possible utility of booster doses, the cohort receiving the highest dose of bivalent antigen will have a 2nd dose administered at Day 84, with a new 7-day reactogenicity diary and sera collected after the 2nd dose. All subjects will be followed up with a 6 month phone call after vaccination or booster.

The total subject observation period will be for 24 weeks from Day 0, plus 12 additional weeks for the cohorts that receive a 2nd dose. With a recruitment period of 4 months, the study duration is expected to be approximately 13 months.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 176 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers
Study Start Date : November 2009
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Active Vaccine
Monovalent rAT or Monovalent rLukS-PV or Bivalent rLukS-PV / rAT
Biological: Monovalent rAT
10, 25, 50 or 100 μg

Biological: Monovalent rLukS-PV
10, 25, 50 or 100 μg

Biological: Bivalent rLukS-PV / rAT
10, 25 or 50 μg

Placebo Comparator: Placebo with Alum Biological: Placebo with adjuvant
Placebo with adjuvant

Placebo Comparator: Saline Placebo Biological: Placebo
Placebo saline

Primary Outcome Measures :
  1. Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports [ Time Frame: Up to 6 months ]
    Adverse events, local reactogenicity, and systemic reactogenicity were assessed through clinical examination by study providers, clinical lab results, as well as review of subject-completed diary

  2. Immunogenicity: Geometric Mean Concentrations After First Injection, Completer Population [ Time Frame: Up to 3 months ]
    Immunogenicity is the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human or animal. Immunogenicity was determined on the basis of anti-rAT and anti-rLukS-PV IgG concentrations assessed by enzyme-linked immunosorbent assay (ELISA) in sera from blood samples collected on Days 0 (baseline), 14, 28 and 84 for those receiving a single dose of vaccine. For those receiving a second dose of vaccine, immunogenicity assessments were also conducted on Days 98 and 112. Immunogenicity was evaluated using the following metrics: geometric mean concentrations (GMCs), geometric mean fold increase (GMFIs) and seroresponse status. Seroresponse variables are normally defined in terms of exceeding a threshold.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy adult males or females, DoD beneficiaries, including active duty members, 18-55 years of age.
  • Negative urine pregnancy test for female subjects of child bearing potential (negative test within 24 hours prior to investigational product injection) or documented surgical sterility.
  • Female subjects of child-bearing potential must use an acceptable method of birth control, as determined by the PI.
  • Willingness to participate in this study as evidenced by written informed consent.

Exclusion Criteria:

  • Prior receipt of S. aureus rAT or rLukS-PV
  • Known S. aureus infection requiring medical treatment within the 3 months prior to investigational drug product injection
  • Known active viral or bacterial infection
  • Seropositivity for HIV infection
  • Known or suspected abuse of prescribed or illicit drugs, or alcohol in the past year
  • Use of any new medications (except oral contraceptives, over-the-counter medications, or vitamin supplements) within the 7 days prior to investigational drug product injection
  • Use of investigational drugs, vaccines, or devices during the study or within the 30 days prior to each dose of investigational drug product injection, or anticipated use of such items during the study
  • Use of systemic steroids (any dose) or high daily dose inhaled steroids within the last month. Use of low or medium daily dose inhaled, intranasal, or low potency topical steroid creams/ointments is allowed unless such medication was begun within the previous 7 days.
  • History of a bleeding or coagulation disorder; or use of anti-coagulant medications within 7 days prior to investigational product injection
  • Actively breastfeeding
  • Presence of grade I or higher abnormality in laboratory or vital signs parameter at time of screening
  • Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01011335

United States, Texas
Brooke Army Medical Center
Fort Sam Houston, Texas, United States, 78234
United States, Virginia
Naval Medical Center Portsmouth
Portsmouth, Virginia, United States, 23708
Sponsors and Collaborators
Uniformed Services University of the Health Sciences
Nabi Biopharmaceuticals
Principal Investigator: Michael L Landrum, MD Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences
Principal Investigator: Paul Kessler, MD Nabi Biopharmaceuticals

Responsible Party: David Tribble, Director, General Infectious Diseases, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences Identifier: NCT01011335     History of Changes
Other Study ID Numbers: IDCRP-035/Nabi-6801
USAMRAA Grant #DR081318P1
First Posted: November 11, 2009    Key Record Dates
Results First Posted: December 12, 2017
Last Update Posted: December 12, 2017
Last Verified: December 2017

Keywords provided by David Tribble, Uniformed Services University of the Health Sciences:
Staphylococcus aureus
Skin and soft tissue infection
Methicillin-resistant Staphylococcus aureus
Recombinant alpha-toxoid (rAT)
Recombinant LukS subunit of Panton-Valentine Leukocidin (rLukS-PV)